Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.

By Richard Eastell, C. Rosen, D. Black, A. Cheung, M. H. Murad, Dolores M. Shoback. Journal of Clinical Endocrinology and Metabolism, 2019

721 citations recorded by the source corpus.

OBJECTIVE The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women. CONCLUSIONS Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles.

Subfields: Genetics, Molecular Biology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/04dd124f846e6e9775f6943dfe01188b1444396d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. M. LeBoff
  2. S. Greenspan
  3. K. Insogna
  4. E. Lewiecki
  5. A. Singer
  6. E. Siris
  7. K. Saag

Citations in the corpus